The proposed Medicare pilot for GLP-1 agonists like semaglutide extends beyond the NYT's cost-focused framing to expose deeper structural flaws in U.S. obesity policy. While the original coverage notes eligibility and projected expenses, it underplays how this builds on patterns from the 2010 Affordable Care Act preventive services expansion and ignores persistent racial disparities in trial enrollment. Peer-reviewed evidence from the STEP 1 RCT (n=1,961 adults, 68-week follow-up, Novo Nordisk-funded with clear disclosure of industry ties) demonstrated 14.9% mean weight loss versus 2.4% placebo, yet real-world observational data from VA cohorts (n>10,000) reveal 40-50% discontinuation rates within one year due to side effects and access barriers. This policy could redirect billions from downstream cardiovascular and diabetes spending, but CMS actuarial models overlook equity gaps seen in prior Medicare Part D expansions. Connecting to the SELECT CVOT RCT (n=17,604, semaglutide arm showing 20% MACE reduction), the expansion may accelerate public health gains, though observational Medicare claims analyses indicate socioeconomic selection effects that favor higher-income beneficiaries. What coverage missed: potential for induced demand inflating spending beyond $150B annually and the absence of long-term adherence RCTs in elderly populations.